REGENXBIO Q4 net loss $67.1M; FDA holds on RGX-121/111; RGX-202 data expected Q2 2026

REGENXBIO Inc.

Q4 2025 net loss $67.1M ($1.30/sh) vs $51.2M loss ($1.01/sh) in Q4 2024; FY net loss $193.9M ($3.76/sh).
Revenues for full year 2025 $170.4M (up from $83.3M in 2024) driven by Nippon Shinyaku partnership and royalty increases.
Cash and marketable securities $240.9M at Dec 31, 2025; expects operations funded into early 2027.
FDA placed clinical holds on RGX-121 and RGX-111; issued Complete Response Letter for RGX-121 BLA in Feb 2026.
RGX-202 for Duchenne: topline pivotal data expected early Q2 2026; pre-BLA meeting mid-2026. Sura-vec wet AMD data expected Q4 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

REGENXBIO Inc. reported financial results for the fourth quarter and year ended December 31, 2025.

Period: the fourth quarter and year ended December 31, 2025
Result: reported results

Exact text from the filing

REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter and year ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

REGENXBIO Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-092566

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.